100 participants
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-13
- Start Date:
- 2020-06-26
- Completion:
- 2025-08-25
Conditions
- Melanoma
Interventions
- BIOLOGICAL
- DRUG